Carolyn D Britten Selected Research

2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- one

12/2017	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
6/2014	Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carolyn D Britten Research Topics

Disease

25	Neoplasms (Cancer) 01/2022 - 07/2002
5	Fatigue 01/2018 - 07/2002
4	Diarrhea 02/2015 - 07/2002
3	Carcinoma (Carcinomatosis) 12/2021 - 07/2017
3	Asthenia 01/2018 - 02/2007
3	Breast Neoplasms (Breast Cancer) 01/2018 - 02/2009
3	Nausea 08/2017 - 07/2002
3	Exanthema (Rash) 02/2015 - 02/2007
2	Embolism (Embolus) 12/2021 - 02/2007
2	Ovarian Neoplasms (Ovarian Cancer) 12/2017 - 02/2015
2	Hepatocellular Carcinoma (Hepatoma) 10/2017 - 02/2009
2	Liver Neoplasms (Liver Cancer) 10/2017 - 01/2012
2	Vomiting 08/2017 - 07/2002
1	Cytokine Release Syndrome 01/2022
1	Adenocarcinoma 01/2020
1	Pneumonia (Pneumonitis) 01/2018
1	Disease Progression 01/2018
1	Colorectal Neoplasms (Colorectal Cancer) 12/2017
1	Endometrial Neoplasms (Endometrial Cancer) 12/2017
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2017
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017
1	Lung Neoplasms (Lung Cancer) 01/2016
1	Stomatitis 02/2015
1	Deglutition Disorders (Dysphagia) 02/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2014
1	Carcinogenesis 06/2013
1	Neoplasm Metastasis (Metastasis) 08/2009
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2009
1	Multiple Myeloma 01/2009
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2009

Drug/Important Bio-Agent (IBA)

6	Pharmaceutical PreparationsIBA 10/2017 - 07/2002
3	PlatinumIBA 01/2018 - 03/2014
3	Trastuzumab (Herceptin)FDA Link 01/2018 - 02/2009
3	Tyrosine Kinase InhibitorsIBA 06/2008 - 02/2007
3	Transaminases (Aminotransferases)IBA 02/2007 - 07/2002
2	Immunoglobulin G (IgG)IBA 12/2021 - 07/2017
2	Monoclonal AntibodiesIBA 12/2021 - 02/2009
2	B7-H1 AntigenIBA 01/2018 - 07/2017
2	avelumabIBA 01/2018 - 07/2017
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2017 - 06/2013
2	2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA 12/2017 - 06/2014
2	ME-344IBA 10/2017 - 01/2016
2	Phosphotransferases (Kinase)IBA 08/2017 - 06/2013
2	Creatine Kinase (Creatine Phosphokinase)IBA 07/2017 - 02/2015
2	Alanine Transaminase (SGPT)IBA 02/2015 - 02/2007
2	Glucose (Dextrose)FDA LinkGeneric 06/2014 - 03/2014
2	Biomarkers (Surrogate Marker)IBA 06/2014 - 06/2006
2	ErbB Receptors (EGF Receptor)IBA 09/2012 - 10/2004
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012 - 02/2009
2	Bevacizumab (Avastin)FDA Link 01/2012 - 02/2009
2	2- methoxy- N- (3- (4- ((3- methyl- 4- ((6- methyl- 3- pyridinyl)oxy)phenyl)amino)- 6- quinazolinyl)- 2- propenyl)acetamideIBA 06/2008 - 02/2007
2	enzastaurinIBA 01/2008 - 06/2006
1	Immunoconjugates (Immunoconjugate)IBA 12/2021
1	Maytansine (Maitansine)IBA 12/2021
1	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 12/2021
1	LY3076226IBA 12/2021
1	Gemcitabine FDA Link 01/2020
1	130-nm albumin-bound paclitaxelIBA 01/2020
1	CC ChemokinesIBA 01/2020
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2020
1	Therapeutic UsesIBA 01/2018
1	Lipase (Acid Lipase)FDA Link 01/2018
1	dactolisibIBA 01/2018
1	mirdametinibIBA 12/2017
1	gedatolisibIBA 12/2017
1	Irinotecan (Camptosar)FDA LinkGeneric 12/2017
1	MTOR InhibitorsIBA 12/2017
1	Topotecan (Hycamtin)FDA LinkGeneric 10/2017
1	Topoisomerase I InhibitorsIBA 10/2017
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 08/2017
1	3- (4- chlorophenyl)- adamantane- 1- carboxylic acid (pyridin-4-ylmethyl)amideIBA 08/2017
1	LipidsIBA 08/2017
1	SphingosineIBA 08/2017
1	poly ICLCIBA 01/2017
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	IsoflavonesIBA 01/2016
1	NVP-BKM120IBA 02/2015
1	trametinibIBA 02/2015
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2015
1	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 10/2014
1	Insulin (Novolin)FDA Link 06/2014
1	C-PeptideIBA 06/2014
1	BIIB022IBA 06/2014
1	Pyruvate Dehydrogenase Acetyl-Transferring KinaseIBA 03/2014
1	LigandsIBA 09/2012
1	Epidermal Growth Factor (EGF)IBA 09/2012
1	dacomitinibIBA 09/2012
1	Lapatinib (GW572016)FDA Link 09/2012
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2009
1	Bortezomib (Velcade)FDA Link 01/2009
1	Antineoplastic Agents (Antineoplastics)IBA 01/2009
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2009
1	EnzymesIBA 01/2009
1	Omeprazole (Prilosec)FDA LinkGeneric 01/2009
1	Cytochrome P-450 CYP3AIBA 01/2009

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 01/2018 - 03/2014
3	Therapeutics 06/2013 - 02/2009
2	Immunotherapy 01/2022 - 01/2017
1	Intravenous Infusions 01/2018